RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Gastroenterology March 22, 2017 at 9:11 AM 0 comments

A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countries The open-label extension study (the MAP US2 study) is intended to assess the safety and efficacy of RHB-104 in patients whoRead More

Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

Hematology, Oncology March 17, 2017 at 11:44 AM 0 comments

Kraków, Poland, March 17, 2017 – Selvita (WSE:SLV),  a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced today that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML). SEL24 is a Selvita-developed first-in-classRead More

Genomic Health Unveils a Wealth of Data for the Oncotype DX® Breast Cancer Test, Reinforcing Its Value in Improving Patient Outcomes and Leading to More Cost-Effective Management

Oncology March 17, 2017 at 9:41 AM 0 comments

15 featured abstracts at the 15th St Gallen International Breast Cancer Conference underscore the growing adoption of the company’s cutting-edge genomic test to identify those patients who will benefit from chemotherapy after breast cancer surgery New real world evidence highlights the significant impact in reducing the burden of unnecessary chemotherapyRead More

Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues

Gastroenterology, Oncology, Respiratory March 15, 2017 at 4:49 PM 0 comments

California, USA, March 15, 2017 – Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs) and circulatingRead More

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Oncology March 14, 2017 at 12:11 PM 0 comments

Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor  Novartis drug Kisqali® (ribociclib, LEE011) receives marketing approval by the US FDA as a first-line drug for HR+/HER2- advanced breast cancer in combination with anRead More

Selvita to Present New Data from its Oncology Programs at the Upcoming AACR Annual Meeting 2017

Oncology March 13, 2017 at 2:23 PM 0 comments

Kraków, Poland, March 13, 2017 – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2017, which will place on April 1-5 2017, in Washington, DC, USA. DataRead More

German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

Oncology March 8, 2017 at 12:24 PM 0 comments

2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer Irvine, CA, USA and Amsterdam, the Netherlands, March 08, 2017 – Agendia, Inc., a world leader in personalized medicine and molecularRead More

2016: Operational Progress and Robust Financial Position for Further Growth

2016: Operational Progress and Robust Financial Position for Further Growth

Uncategorized March 7, 2017 at 2:48 PM 0 comments

Cash, cash equivalents and financial instruments* amounted to €230.7m (million euros) as of December 31, 2016 Revenue and other income amounted to €65.7m (€25.1m in 2015), including $15m (€13.8m) milestone payment from Bristol-Myers Squibb related to progress with lirilumab Operating expenses amounted to €58.2m (€35.9m in 2015); increase driven byRead More

Mental Health Specialist Commends UK Grime Star’s Bravery on Depression

Neurology March 7, 2017 at 1:54 PM 0 comments

March 7, 2017 – Following recent news that reveals a quarter of men self-harm in order to cope with depression, UK grime artist Stormzy’s live television discussion on his experiences with depression has been highly praised by a mental health specialist. Stormzy, (Michael Omari),  opened up about his battle withRead More

Pfizer Selects Turner & Townsend for Expansion of Its Clinical Research Unit in Belgium

Uncategorized March 6, 2017 at 2:49 PM 0 comments

Global consultancy Turner & Townsend provides project, cost and commercial management services for two fit outs in Brussels, Belgium First part of the project involved the refurbishment of 578 sq m of office accommodating 60 people and a new subject screening area Turner & Townsend is currently working on aRead More